Experts will gather in Seoul this month to discuss the importance of regulatory science in the bio-health industry and strategies for further advancement.
The Korean Society of Food, Drug and Cosmetics Regulatory Sciences (KFDC) said at a news conference on Friday that it would hold a conference on regulatory science and strategies for the new bio-health industry at the K Hotel Seoul in southern Seoul on June 24.
The event will be in-person only, following the government’s easing of social distancing.
The forum will consist of a keynote lecture and four sessions.
Kang Seok-yeon, director-general of the Food and Drug Safety Bureau at the Ministry of Food and Drug Safety (MFDS), will deliver the keynote lecture on the development of the pharmaceutical and biopharmaceutical industry and the regulatory science of the MFDS.
Industry officials, government officials, scholars, and researchers will present lectures and discuss issues on four topics -- current status and development direction of regulatory science research and application cases, new personalized bio-health industry and regulatory science’s tasks, regulatory science’s role in improving drug quality, and “my health way” and strategies for the new bio-health industry.
The current status and development direction of regulatory science research and application cases will draw particular attention because they will be jointly presented by the Korea Regulatory Science Center and KFDC.
Experts will discuss recent studies on regulatory science and future growth directions.
Won Kwon-yeon, secretary-general of the KFDC, said regulations keep updated, and pharmaceutical companies should keep meeting the updated standards, as seen in the “current” Good Manufacturing Practice (cGMP).
“Korean pharmaceutical products recorded a trade surplus, and to continue this trend, Korean drugs should meet the quality required by each country,” he said.
Won pointed out that some Korean manufacturers still have low-quality issues, including GMP violations.
The KFDC will continue to deal with these issues and update information together with the industry, he added.
Sohn Yeo-won, president of the KFDC, said regulatory science has emerged as an important factor in advancing the Korean pharmaceutical and biotech industry.
The upcoming conference will be an opportunity to discuss regulatory science's role in improving pharmaceutical product quality and developing a new bio-health industry, she said.
Although people have a consensus that bio-health innovations need regulatory science, she noted that they have yet to discuss what kind of collaboration is needed between the industry and the regulatory science community.
“As the new government picked the bio-health sector as a new growth engine, the upcoming conference on regulatory science will be helpful for government administration,” she added.
Details on the conference and registration are available on the website of the KFDC at http://www.kfdc.or.kr.